NuvaringNuvaRing® is a vaginal contraceptive ring manufactured by Merck and Co., formerly known as Organon. The active ingredients of NuvaRing® are progestin (in the form of etonogestrel) and estrogen (in the form of ethinylestradiol). Organon released the product in 2002 after the U.S. Food and Drug Administration (FDA) approved its use.

Why Is the Manufacturer Subject to Lawsuits?

The etonogestrel used in NuvaRing® is a third-generation progestin. Like other third-generation progestins, etonogestrel is associated with a higher risk of possible blood clots than is found with other forms of birth control.

Since NuvaRing’s release, the U.S. Food and Drug Administration (FDA) has received reports of various adverse events associated with its use. The most dangerous side effect reported of NuvaRing® is blood clotting, which can lead to heart attack, stroke, and even death. In 2005, the FDA required Organon to update the label to more accurately reflect the risks associated with their NuvaRing® product. Lawsuits have skyrocketed against Merck and Co. from about 700 in April 2011 to over 1,000 as of May 2013.

Saint Louis Defective Birth Control Products Attorney’s Warning

Although NuvaRing® is still FDA-approved for use, please be aware of the severe results that have occurred including:

·       Heart Attack

·       Ishemic Stroke

·       Blood clotting in the legs or arms (deep vein thrombosis/DVT)

·       Blood clotting in the lungs (pulmonary embolism/PE)

You should discuss your options with your physician and carefully weigh the benefits against the risks to decide on a contraceptive option that is best for you.

If you or someone you know has suffered from any of these issues after using NuvaRing, do not hesitate to seek answers.

For further questions please contact Lieser Law Firm today.